

The easing tensions between the two Koreas;

Steps toward the reunification of families; and

The eventual reunification of the peninsula.

I look forward, as we all should, to viewing the details that accompany these understandings with real hope that the two Koreas are on a path toward true and lasting peace. While this summit is only a first step, I am pleased and encouraged by its apparent success. I urge the leaders of North and South Korea to remain committed to this historic process that they have initiated.

Finally, Mr. Speaker, let me close by quoting from President Kim's airport speech in Seoul. Before he boarded the plane for Pyongyang, he said:

I want to embark on the trip with a heart burning with love for our people and a calm attitude so that I can look straight at reality. I hope that it will be a turning point in efforts to remove threats to war and terminate the Cold War . . . so that 70 million Korean people in the north and south can live in peace.

Mr. Speaker, we hope that President Kim is correct and I invite my colleagues to join in wishing him success in this important endeavor.

RECOGNIZING WORLD IMPACT,
INC.

HON. GEORGE RADANOVICH

OF CALIFORNIA

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 28, 2000

Mr. RADANOVICH. Mr. Speaker, I rise today to recognize the Fresno Chapter of World Impact, Inc. for their effect on the Fresno Community.

World Impact is a nationwide, interdenominational, Christian discipling and church-planting ministry dedicated to ministering God's love in the inner cities of America. The organization nurtures urban disciples who will join in teaching others the gospel. World Impact, Inc. also develops indigenous disciples of Christ in the inner city through ministry to children, teenagers and adults who are committed to Christ and to making Him known to others.

Currently, the Fresno Chapter shares the gospel of Jesus Christ in five ministry areas in Fresno, California. They minister to about 250 children and 40 teenagers weekly from these areas and also hold Bible studies for adults. In addition to their five ministry areas, they also have a community center, which includes a gymnasium, recreation rooms, a kitchen, offices, and classrooms. The community center offers Bible classes year round, as well as other community activities.

Mr. Speaker, I want to recognize the Fresno chapter of World Impact, Inc. for their contributions to the community, and I urge my colleagues to join me in wishing the organization many more years of continued success.

CONGRATULATIONS TO GAIL
NAUGHTON, PH.D., INVENTOR OF
THE YEAR

HON. RANDY "DUKE" CUNNINGHAM

OF CALIFORNIA

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 28, 2000

Mr. CUNNINGHAM. Mr. Speaker, today I congratulate my constituent, Gail Naughton. Today, the Intellectual Property Owner's Association will name Dr. Naughton Inventor of the Year. As the first individual woman to win this award, Dr. Naughton is being honored for the process she invented to produce human tissues and organs outside the human body.

Traditionally, growing cells in a laboratory consisted of placing cells on a flat surface with a growth medium. In this process, cells behaved differently than their natural counterparts. Dr. Naughton's invention utilizes stroma cells, which are the cells that form the surrounding matrix of the tissue. Using a three-dimensional scaffolding, which is placed in a specially designed "bioreactor", Dr. Naughton was able to simulate the body making it possible for cells to form a tissue matrix that was virtually undistinguishable from those found in nature. Dr. Naughton's pioneering work in tissue engineering has defined a new industry dedicated to helping the millions of people who suffer tissue loss or end-stage organ failure. In addition, cartilage, heart tissue and other organs can be bioengineered with this unique human-based technology, which has the potential of addressing the significant shortage of world wide donor organs.

Dr. Naughton is the co-founder and President and Chief Operating Officer of Advanced Tissue Sciences, Inc. in La Jolla, California where she has developed product technology to help patients and to respond to the growing need for transplant tissues and organs. A mother of three, she received her MS in histology in 1978 and Ph.D. in 1981, both from NYU. She has been published extensively in the field of tissue engineering and is the holder of 26 U.S. patents. Through the Advanced Tissue Sciences, Dr. Naughton has produced various therapeutic products such as Transcyte™, which is used to treat second and third degree burns, and Dermagraft®, which is used for the treatment of diabetic foot ulcers. These products represent advancements in bioengineering, manufacturing, and cytopreservation in an emerging industry.

Dr. Naughton is also on the advisory boards of the Department of Bioengineering at Johns Hopkins University and Georgia Institute of Technology, and is a member of the industrial liaison board at the University of California, San Diego, the Georgia Institute of Technology, MIT, and the University of Washington. She is also a member of the board of Directors of Scripps Bank in La Jolla, California, the San Diego Burn Institute and the Charles H. and Anna S. Stern Foundation. In 1999, she received a "Woman Who Mean Business" award from the San Diego Business Journal.

Gail Naughton deserves our congratulations for this tremendous achievement. I know that she is proud of her accomplishments, and I am proud to have her as my constituent.

SEVERE SHORTAGE OF APPROVED
ANIMAL DRUGS

HON. CHARLES W. "CHIP" PICKERING

OF MISSISSIPPI

IN THE HOUSE OF REPRESENTATIVES

Wednesday, June 28, 2000

Mr. PICKERING. Mr. Speaker, I rise today in order to bring attention to a problem faced by livestock and food animal producers, animal and pet owners, zoo and wildlife biologists, and the animals themselves, which unfortunately goes largely unnoticed except by those who are directly affected.

There currently exists a severe shortage of approved animal drugs for use in minor animal species. These minor animal species include animals other than cattle, horses, chickens, turkeys, dogs, and cats. In addition, there also exists a similar shortage of drugs and medicines for major animal species for diseases that occur infrequently or which occur in limited geographic areas. Due to the lack of availability of these minor use drugs, millions of animals go either untreated or treatment is delayed. This results not only in unnecessary animal physical and human emotional suffering but may threaten human health as well.

Because of limited market opportunity, low profit margins involved, and enormous capital investment required, it is generally not economically feasible for drug manufacturers to pursue research and development and then approval for drugs used in treating minor species and infrequent conditions and diseases.

In addition to the animals themselves, without access to these necessary minor use drugs, farmers and ranchers also suffer. An unhealthy animal that is left untreated can spread disease throughout an entire stock of its fellow specie causing severe economic hardship to struggling ranchers and farmers.

For example, Mr. Speaker, sheep ranchers lost nearly \$45 million worth of livestock alone in 1999. The sheep industry estimates that if it had access to effective and necessary drugs, growers' reproduction costs for their animals would be cut by up to 15%. In addition, feedlot deaths would be reduced to 1–2% adding approximately \$8 million of revenue to the industry.

The catfish industry, a top agriculture industry in my home state of Mississippi generating enormous economic opportunity in the State, especially in the impoverished Mississippi Delta, estimates its losses at \$60 million per year attributable to diseases for which drugs are not available. The U.S. aquaculture industry overall, including food as well as ornamental fish, produces and raises over 800 different species. Unfortunately, this industry has only 5 drugs approved for use in treating aquaculture diseases resulting in tremendous economic hardship and animal suffering.

Mr. Speaker, joined with my colleagues Mr. HALL of Texas, Mr. COMBEST of Texas, Mr. STENHOLM of Texas, and Mr. POMBO of California, I resolve to correct this unfortunate situation by introducing the Minor Animal Species Health and Welfare Act of 2000. This legislation will allow pharmaceutical companies the opportunity to develop and approve minor use drugs which are vitally needed by a plethora of animal industries. Our legislation incorporates the major proposals of the FDA's Center for Veterinary Medicine to increase the availability of drugs for minor animal species